BACKGROUND: Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70-80% of pediatric cases) and accounts for 10-15% of all childhood lymphomas. Treatment strategies for pediatric ALCL vary from short pulse B-NHL chemotherapy to prolonged leukemia like therapy. The optimal treatment strategy is unknown. METHODS: CCG-5941 used a compressed aggressive multiagent T-cell lineage chemotherapy regimen consisting of a 3-week induction therapy (vincristine, prednisone, cyclophosphamide, daunomycin, asparaginase) followed by a 3-week consolidation period (vincristine, prednisone, etoposide, 6-thioguanine, cytarabine, asparaginase, methotrexate) followed by six courses of maintenance chemotherapy at 7-week intervals (cyclophosphamide, 6-thioguanine, vincristine, prednisone, doxorubicin, asparaginase, methotrexate etoposide, cytarabine). Total therapy was 48 weeks. RESULTS: Eighty-six children (male 56%, female 44%) with non-localized ALCL (CD30+) were treated. The majority of tumors were positive for ALK (90%) and of T lineage (83%). Extranodal disease was common (mediastinum 35%, skin 15%, lung 14%, bone 12%, bone marrow 13%, liver 6%, and other viscera 17%). Grade 4 neutropenia occurred in 82% of patients. The 5-year EFS was 68% (95% CI of 57-78%) and the 5-year OS was 80% (95% CI of 69-87%). There were 21 relapses and 4 toxic deaths as first events. Relapse occurred early with 17 (81%) relapses occurring within 2 years of diagnosis and 12 (57%) while receiving therapy. Univariate analysis for risk factors only identified bone marrow involvement predicting lower EFS (P = 0.03). CONCLUSIONS: CCG-5941 demonstrated efficacy similar to previously reported regimens but with significant hematologic toxicity.
BACKGROUND:Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70-80% of pediatric cases) and accounts for 10-15% of all childhood lymphomas. Treatment strategies for pediatric ALCL vary from short pulse B-NHL chemotherapy to prolonged leukemia like therapy. The optimal treatment strategy is unknown. METHODS: CCG-5941 used a compressed aggressive multiagent T-cell lineage chemotherapy regimen consisting of a 3-week induction therapy (vincristine, prednisone, cyclophosphamide, daunomycin, asparaginase) followed by a 3-week consolidation period (vincristine, prednisone, etoposide, 6-thioguanine, cytarabine, asparaginase, methotrexate) followed by six courses of maintenance chemotherapy at 7-week intervals (cyclophosphamide, 6-thioguanine, vincristine, prednisone, doxorubicin, asparaginase, methotrexateetoposide, cytarabine). Total therapy was 48 weeks. RESULTS: Eighty-six children (male 56%, female 44%) with non-localized ALCL (CD30+) were treated. The majority of tumors were positive for ALK (90%) and of T lineage (83%). Extranodal disease was common (mediastinum 35%, skin 15%, lung 14%, bone 12%, bone marrow 13%, liver 6%, and other viscera 17%). Grade 4 neutropenia occurred in 82% of patients. The 5-year EFS was 68% (95% CI of 57-78%) and the 5-year OS was 80% (95% CI of 69-87%). There were 21 relapses and 4 toxic deaths as first events. Relapse occurred early with 17 (81%) relapses occurring within 2 years of diagnosis and 12 (57%) while receiving therapy. Univariate analysis for risk factors only identified bone marrow involvement predicting lower EFS (P = 0.03). CONCLUSIONS: CCG-5941 demonstrated efficacy similar to previously reported regimens but with significant hematologic toxicity.
Authors: H Tilly; P Gaulard; E Lepage; C Dumontet; J Diebold; I Plantier; F Berger; M Symann; T Petrella; P Lederlin; J Brière Journal: Blood Date: 1997-11-01 Impact factor: 22.113
Authors: R D Gascoyne; P Aoun; D Wu; M Chhanabhai; B F Skinnider; T C Greiner; S W Morris; J M Connors; J M Vose; D S Viswanatha; A Coldman; D D Weisenburger Journal: Blood Date: 1999-06-01 Impact factor: 22.113
Authors: L Brugières; P Quartier; M C Le Deley; H Pacquement; Y Perel; C Bergeron; C Schmitt; J Landmann; C Patte; M J Terrier-Lacombe; G Delsol; O Hartmann Journal: Ann Oncol Date: 2000-01 Impact factor: 32.976
Authors: Marie-Cécile Le Deley; Alfred Reiter; Denise Williams; Georges Delsol; Ilske Oschlies; Keith McCarthy; Martin Zimmermann; Laurence Brugières Journal: Blood Date: 2007-10-23 Impact factor: 22.113
Authors: J T Sandlund; C H Pui; V M Santana; H Mahmoud; W M Roberts; S Morris; S Raimondi; R Ribeiro; W M Crist; J S Lin Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: L Brugières; M C Deley; H Pacquement; Z Meguerian-Bedoyan; M J Terrier-Lacombe; A Robert; C Pondarré; G Leverger; C Devalck; C Rodary; G Delsol; O Hartmann Journal: Blood Date: 1998-11-15 Impact factor: 22.113
Authors: H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke Journal: Blood Date: 1985-10 Impact factor: 22.113
Authors: J T Sandlund; C H Pui; W M Roberts; V M Santana; S W Morris; C W Berard; R E Hutchison; R C Ribeiro; H Mahmoud; W M Crist Journal: Blood Date: 1994-10-15 Impact factor: 22.113
Authors: Denise M Williams; Rachel Hobson; John Imeson; Mary Gerrard; Keith McCarthy; C Ross Pinkerton Journal: Br J Haematol Date: 2002-06 Impact factor: 6.998
Authors: Sarah Alexander; Jacqueline M Kraveka; Sheila Weitzman; Eric Lowe; Lynette Smith; James C Lynch; Myron Chang; Marsha C Kinney; Sherrie L Perkins; Joseph Laver; Thomas G Gross; Howard Weinstein Journal: Pediatr Blood Cancer Date: 2014-08-23 Impact factor: 3.167
Authors: John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia Journal: Target Oncol Date: 2012-09-12 Impact factor: 4.493